A new trading day began on Monday, with Ginkgo Bioworks Holdings Inc (NYSE: DNA) stock price down -8.23% from the previous day of trading, before settling in for the closing price of $11.66. DNA’s price has ranged from $5.26 to $75.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 104.75%. Meanwhile, its annual earnings per share averaged 45.22%. With a float of $36.31 million, this company’s outstanding shares have now reached $41.37 million.
The extent of productivity of a business whose workforce counts for 1218 workers is very important to gauge. In terms of profitability, gross margin is 63.73%, operating margin of -271.32%, and the pretax margin is -298.94%.
Ginkgo Bioworks Holdings Inc (DNA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Ginkgo Bioworks Holdings Inc is 33.34%, while institutional ownership is 47.97%. The most recent insider transaction that took place on Dec 09 ’24, was worth 1,178. Before that another transaction happened on Dec 06 ’24, when Company’s Officer proposed sale 99 for $9.80, making the entire transaction worth $970.
Ginkgo Bioworks Holdings Inc (DNA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 45.22% per share during the next fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Here are Ginkgo Bioworks Holdings Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.79. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.90, a number that is poised to hit -1.50 in the next quarter and is forecasted to reach -5.88 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
The latest stats from [Ginkgo Bioworks Holdings Inc, DNA] show that its last 5-days average volume of 1.82 million was superior to 1.16 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 81.33%. Additionally, its Average True Range was 0.91.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 48.87%, which indicates a significant decrease from 78.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 111.65% in the past 14 days, which was higher than the 110.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.21, while its 200-day Moving Average is $20.41. Now, the first resistance to watch is $11.59. This is followed by the second major resistance level at $12.49. The third major resistance level sits at $12.99. If the price goes on to break the first support level at $10.19, it is likely to go to the next support level at $9.69. Assuming the price breaks the second support level, the third support level stands at $8.79.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
With a market capitalization of 741.59 million, the company has a total of 57,479K Shares Outstanding. Currently, annual sales are 251,460 K while annual income is -892,870 K. The company’s previous quarter sales were 89,050 K while its latest quarter income was -56,400 K.
